Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor. Isomorphic ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round. OpenAI backer Thrive Capital led the investment.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital ...

Isomorphic Labs has raised $600m in its first external funding round as it pushes forward with artificial intelligence (AI)-driven drug discovery. Thrive Capital led the financing round, with ...

AlphaFold’s success would pave the way for Isomorphic Labs, a spinoff focused on AI-driven drug discovery. Isomorphic was founded in 2021, but it wasn’t until yesterday that the company ...

Isomorphic Labs was spun out of DeepMind in 2021 as a commercial venture, aiming to 'reimagine' the entire drug discovery process Isomorphic Labs, a subsidiary of Google parent Alphabet that uses ...

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million, the first time it’s taken in external funding. The round was led by ...